Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: A recent update

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Guo, Yuan ^a   Lu, Nonghua ^a   Bai, Aiping ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERSTITIAL COLLAGENASE; MESSENGER RNA; NITRIC OXIDE; PLACEBO; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CELLULAR IMMUNITY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOTHELIAL DYSFUNCTION; ENTERITIS; ENZYME REGULATION; ENZYME RELEASE; HOMOZYGOTE; HUMAN; IMMUNOMODULATION; INHIBITION KINETICS; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; LEUKOCYTE MIGRATION; MACROPHAGE; MAINTENANCE THERAPY; MULTICENTER STUDY (TOPIC); MYOFIBROBLAST; PHARMACOGENETICS; PHARMACOLOGICAL BLOCKING; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCER HEALING; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PATHOLOGY; DRUG ANTAGONISM; INFLAMMATORY BOWEL DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874619851     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/581631     Document Type: Review

References (92)

1. Xavier R. J., Podolsky D. K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007 448 7152 427 434 2-s2.0-34547176642 10.1038/nature06005 (Pubitemid 47123518)
2. Kamada N., Hisamatsu T., Okamoto S., Sato T., Matsuoka K., Arai K., Nakai T., Hasegawa A., Inoue N., Watanabe N., Akagawa K. S., Hibi T., Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. Journal of Immunology 2005 175 10 6900 6908 2-s2.0-27744437941 (Pubitemid 41598935)
3. Bai A. P., Ouyang Q., Probiotics and inflammatory bowel diseases. Postgraduate Medical Journal 2006 82 968 376 382 2-s2.0-33745413808 10.1136/pgmj.2005.040899 (Pubitemid 43945473)
4. Papadakis K. A., Targan S. R., Role of cytokines in the pathogenesis of inflammatory bowel disease. Annual Review of Medicine 2000 51 289 298 2-s2.0-0034005581 10.1146/annurev.med.51.1.289 (Pubitemid 30216038)
5. Apostolaki M., Armaka M., Victoratos P., Kollias G., Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Current Directions in Autoimmunity 2010 11 1 26 2-s2.0-77949442340 10.1159/000289195
6. Khor B., Gardet A., Xavier R. J., Genetics and pathogenesis of inflammatory bowel disease. Nature 2011 474 7351 307 317 2-s2.0-79959216005 10.1038/nature10209
7. Komatsu M., Kobayashi D., Saito K., Furuya D., Yagihashi A., Araake H., Tsuji N., Sakamaki S., Niitsu Y., Watanabe N., Tumor necrosis factor- α in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clinical Chemistry 2001 47 7 1297 1301 2-s2.0-0034956578 (Pubitemid 32579119)
8. Stevens C., Walz G., Singaram C., Lipman M. L., Zanker B., Muggia A., Antonioli D., Peppercorn M. A., Strom T. B., Tumor necrosis factor- α interleukin-1 β and interleukin-6 expression in inflammatory bowel disease. Digestive Diseases and Sciences 1992 37 6 818 826 2-s2.0-0026689516 10.1007/BF01300378
9. Wang J., Fu Y. X., Tumor necrosis factor family members and inflammatory bowel disease. Immunological Reviews 2005 204 144 155 2-s2.0-16244410786 10.1111/j.0105-2896.2005.00218.x (Pubitemid 40460499)
10. Nikolaus S., Raedler A., Kühbacher T., Sfikas N., Fölsch U. R., Schreiber S., Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000 356 9240 1475 1479 2-s2.0-0034727474
11. Rutgeerts P., Van Assche G., Vermeire S., Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004 126 6 1593 1610 2-s2.0-2442560241 10.1053/j.gastro.2004.02.070 (Pubitemid 38649876)
12. Sandborn W. J., Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 2008 135 5 1442 1447 2-s2.0-55249091834 10.1053/j.gastro.2008.09.053
13. D'Haens G., Daperno M., Advances in biologic therapy for ulcerative colitis and Crohn's disease. Current Gastroenterology Reports 2006 8 6 506 512 2-s2.0-33845896308 10.1007/s11894-006-0041-5 (Pubitemid 46017163)
14. Rutgeerts P., Vermeire S., Van Assche G., Biological therapies for inflammatory bowel diseases. Gastroenterology 2009 136 4 1182 1197 2-s2.0-62949219864 10.1053/j.gastro.2009.02.001
15. Yamamoto-Furusho J. K., Innovative therapeutics for inflammatory bowel disease. World Journal of Gastroenterology 2007 13 13 1893 1896 2-s2.0-34248582436 (Pubitemid 46746374)
16. Danese S., Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Digestive and Liver Disease 2008 40 supplement 2 S225 S228 2-s2.0-45849083467 10.1016/S1590-8658(08)60530-7 (Pubitemid 351878064)
17. Cornillie F., Shealy D., D'Haens G., Geboes K., Van Assche G., Ceuppens J., Wagner C., Schaible T., Plevy S. E., Targan S. R., Rutgeerts P., Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics 2001 15 4 463 473 2-s2.0-17744373658 10.1046/j.1365-2036.2001.00956.x (Pubitemid 32242771)
18. Atzeni F., Turiel M., Capsoni F., Doria A., Meroni P., Sarzi-Puttini P., Autoimmunity and anti-TNF- α agents. Annals of the New York Academy of Sciences 2005 1051 559 569 2-s2.0-25444502974 10.1196/annals.1361.100 (Pubitemid 41362783)
19. Stokkers P. C. F., Hommes D. W., New cytokine therapeutics for inflammatory bowel disease. Cytokine 2004 28 4-5 167 173 2-s2.0-9644252669 10.1016/j.cyto.2004.07.012 (Pubitemid 39573504)
20. Ljung T., Axelsson L. G., Herulf M., Lundberg J. O., Hellström P. M., Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment. Alimentary Pharmacology and Therapeutics 2007 25 8 925 932 2-s2.0-34047159242 10.1111/j.1365-2036.2007. 03284.x (Pubitemid 46525348)
21. Agnholt J., Kelsen J., Brandsborg B., Jakobsen N. O., Dahlerup J. F., Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease-a possible target for infliximab treatment. European Journal of Gastroenterology and Hepatology 2004 16 7 649 655 2-s2.0-3142588819 10.1097/01.meg.0000108344.41221.8b (Pubitemid 38901632)
22. Van den Brande J. M. H., Braat H., van den Brink G. R., Versteeg H. H., Bauer C. A., Hoedemaeker I., Van Montfrans C., Hommes D. W., Peppelenbosch M. P., Van Deventer S. J. H., Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003 124 7 1774 1785 2-s2.0-0038047689 10.1016/S0016-5085(03) 00382-2 (Pubitemid 36666774)
23. Di Sabatino A., Ciccocioppo R., Cinque B., Millimaggi D., Morera R., Ricevuti L., Cifone M. G., Corazza G. R., Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004 53 1 70 77 2-s2.0-0346461662 10.1136/gut.53.1.70 (Pubitemid 38083013)
24. ten Hove T., Van Montfrans C., Peppelenbosch M. P., Van Deventer S. J. H., Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002 50 2 206 211 2-s2.0-0036151047 10.1136/gut.0500206. (Pubitemid 34087933)
25. Mannon P. J., Fuss I. J., Mayer L., Elson C. O., Sandborn W. J., Present D., Dolin B., Goodman N., Groden C., Hornung R. L., Quezado M., Neurath M. F., Salfeld J., Veldman G. M., Schwertschlag U., Strober W., Anti-interleukin-12 antibody for active Crohn's disease. The New England Journal of Medicine 2004 351 20 2069 2079 2-s2.0-8344284998 10.1056/NEJMoa033402 (Pubitemid 39482500)
26. Andou A., Hisamatsu T., Okamoto S., Chinen H., Kamada N., Kobayashi T., Hashimoto M., Okutsu T., Shimbo K., Takeda T., Matsumoto H., Sato A., Ohtsu H., Suzuki M., Hibi T., Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 2009 136 2 564 574.e2 2-s2.0-58649086521 10.1053/j.gastro.2008.09.062
27. + intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN- γ axis. Journal of Clinical Investigation 2008 118 6 2269 2280 2-s2.0-45749107055 10.1172/JCI34610 (Pubitemid 351872344)
28. Agnholt J., Kaltoft K., Infliximab downregulates interferon- γ production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001 15 4 212 222 2-s2.0-0035928895 10.1006/cyto.2001.0919 (Pubitemid 34587646)
29. Veltkamp C., Anstaett M., Wahl K., Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFalpha treatment. Gut 2011 60 1345 1353 10.1136/gut.2010.217117
30. + regulatory T cells in children affected by Crohn's disease. Immunology 2008 125 2 178 183 2-s2.0-51249084103 10.1111/j.1365-2567.2008.02839.x
31. Fleming B. D., Mosser D. M., Regulatory macrophages: setting the threshold for therapy. European Journal of Immunology 2011 41 9 2498 2502 10.1002/eji.201141717
32. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Assche G. V., Geboes K., Ceuppens J. L., Rutgeerts P., Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. American Journal of Gastroenterology 2002 97 8 2000 2004 2-s2.0-0036678630 10.1016/S0002-9270(02) 04271-5
33. Zeissig S., Bojarski C., Buergel N., Mankertz J., Zeitz M., Fromm M., Schulzke J. D., Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor α antibody treatment. Gut 2004 53 9 1295 1302 2-s2.0-4344700784 10.1136/gut.2003.036632 (Pubitemid 39120115)
34. Arijs I., De Hertogh G., Machiels K., Van Steen K., Lemaire K., Schraenen A., Van Lommel L., Quintens R., Van Assche G., Vermeire S., Schuit F., Rutgeerts P., Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. American Journal of Gastroenterology 2011 106 4 748 761 2-s2.0-79953800521 10.1038/ajg.2011.27
35. Schinzari F., Armuzzi A., De Pascalis B., Mores N., Tesauro M., Melina D., Cardillo C., Tumor necrosis factor- α antagonism improves endothelial dysfunction in patients with Crohn's disease. Clinical Pharmacology and Therapeutics 2008 83 1 70 76 2-s2.0-37549028415 10.1038/sj.clpt.6100229
36. Scaldaferri F., Vetrano S., Sans M., Arena V., Straface G., Stigliano E., Repici A., Sturm A., Malesci A., Panes J., Yla-Herttuala S., Fiocchi C., Danese S., VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009 136 2 585 595.e5 2-s2.0-58649111743 10.1053/j.gastro.2008.09.064
37. Meijer M. J., Mieremet-Ooms M. A. C., van Duijn W., Van Der Zon A. M., Hanemaaijer R., Verheijen J. H., Van Hogezand R. A., Lamers C. B. H. W., Verspaget H. W., Effect of the anti-tumor necrosis factor- α antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflammatory Bowel Diseases 2007 13 2 200 210 2-s2.0-34249341647 10.1002/ibd.20051 (Pubitemid 46806229)
38. Di Sabatino A., Pender S. L. F., Jackson C. L., Prothero J. D., Gordon J. N., Picariello L., Rovedatti L., Docena G., Monteleone G., Rampton D. S., Tonelli F., Corazza G. R., MacDonald T. T., Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007 133 1 137 149 2-s2.0-34447093806 10.1053/j.gastro.2007.04. 069 (Pubitemid 47031137)
39. Kierkus J., Dadalski M., Szymanska E., The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease. European Journal of Gastroenterology & Hepatology 2012 24 5 495 500 10.1097/MEG.0b013e32835159f2
40. Guidi L., Costanzo M., Ciarniello M., Increased levels of NF-kappaB inhibitors (IkappaBalpha and IkappaBgamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment. International Journal of Immunopathology and Pharmacology 2005 18 1 155 164 (Pubitemid 40343468)
41. Waetzig G. H., Seegert D., Rosenstiel P., Nikolaus S., Schreiber S., p38 mitogen-activated protein kinase is activated and linked to TNF- α signaling in inflammatory bowel disease. Journal of Immunology 2002 168 10 5342 5351 2-s2.0-0037093877 (Pubitemid 34496003)
42. Steenholdt C., Svenson M., Bendtzen K., Thomsen O. A., Brynskov J., Ainsworth M. A., Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2011 34 1 51 58 2-s2.0-79958095982 10.1111/j.1365-2036.2011.04682.x
43. Sherlock M., Bandsma R., Ota K., Kirby-Allen M., Griffiths A., Severe neutropenia following infliximab treatment in a child with ulcerative colitis. Inflammatory Bowel Diseases 2011 17 2 E17 E18 2-s2.0-78651327288 10.1002/ibd.21466
44. Veereman-Wauters G., de Ridder L., Veres G., Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary. Journal of Pediatric Gastroenterology & Nutrition 2012 54 6 830 837 10.1097/MPG.0b013e31824d1438
45. Schneeweiss S., Korzenik J., Solomon D. H., Canning C., Lee J., Bressler B., Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Alimentary Pharmacology and Therapeutics 2009 30 3 253 264 2-s2.0-67650430007 10.1111/j.1365-2036.2009.04037.x
46. Miele E., Markowitz J. E., Mamula P., Baldassano R. N., Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. Journal of Pediatric Gastroenterology and Nutrition 2004 38 5 502 508 2-s2.0-3543106683
47. Biancone L., Petruzziello C., Orlando A., Kohn A., Ardizzone S., Daperno M., Angelucci E., Castiglione F., D'Incã R., Zorzi F., Papi C., Meucci G., Riegler G., Sica G., Rizzello F., Mocciaro F., Onali S., Calabrese E., Cottone M., Pallone F., Cancer in Crohn's disease patients treated with infliximab: a long-term multicenter matched pair study. Inflammatory Bowel Diseases 2011 17 3 758 766 2-s2.0-79951650570 10.1002/ibd.21416
48. Kelsen J., Dige A., Schwindt H., D'Amore F., Pedersen F. S., Agnholt J., Christensen L. A., Dahlerup J. F., Hvas C. L., Infliximab induces clonal expansion of γ δ -T cells in Crohn's disease: a predictor of lymphoma risk? PLoS One 2011 6 3, article e17890 2-s2.0-79953329803 10.1371/journal.pone.0017890
49. Iborra M., Beltrán B., Bastida G., Aguas M., Nos P., Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. Journal of Crohn's and Colitis 2011 5 2 157 161 2-s2.0-79953099459 10.1016/j.crohns.2010.11.001
50. Targan S. R., Hanauer S. B., Van Deventer S. J. H., Mayer L., Present D. H., Braakman T., DeWoody K. L., Schaible T. F., Rutgeerts P. J., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. The New England Journal of Medicine 1997 337 15 1029 1035 2-s2.0-0030954732 10.1056/NEJM199710093371502 (Pubitemid 27430520)
51. Hanauer S. B., Feagan B. G., Lichtenstein G. R., Mayer L. F., Schreiber S., Colombel J. F., Rachmilewitz D., Wolf D. C., Olson A., Bao W., Rutgeerts P., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 9317 1541 1549 2-s2.0-0037018761 10.1016/S0140-6736(02)08512-4 (Pubitemid 34621118)
52. Desilva S., Kaplan G., Panaccione R., Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. Reviews in Gastroenterological Disorders 2008 8 2 109 116 2-s2.0-46749096760 (Pubitemid 351947610)
53. Swaminath A., Lichtiger S., Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflammatory Bowel Diseases 2008 14 2 213 216 2-s2.0-39649115628 10.1002/ibd.20318 (Pubitemid 351288042)
54. Taxonera C., Schwartz D. A., García-Olmo D., Emerging treatments for complex perianal fistula in Crohn's disease. World Journal of Gastroenterology 2009 15 34 4263 4272 2-s2.0-70349580667 10.3748/wjg.15.4263
55. Sands B. E., Anderson F. H., Bernstein C. N., Chey W. Y., Feagan B. G., Fedorak R. N., Kamm M. A., Korzenik J. R., Lashner B. A., Onken J. E., Rachmilewitz D., Rutgeerts P., Wild G., Wolf D. C., Marsters P. A., Travers S. B., Blank M. A., Van Deventer S. J., Infliximab maintenance therapy for fistulizing Crohn's disease. The New England Journal of Medicine 2004 350 9 876 885 2-s2.0-10744221312 10.1056/NEJMoa030815 (Pubitemid 38252535)
56. Rutgeerts P., Sandborn W. J., Feagan B. G., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S. B., Lichtenstein G. R., De Villiers W. J. S., Present D., Sands B. E., Colombel J. F., Infliximab for induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine 2005 353 23 2462 2476 2-s2.0-28844473957 10.1056/NEJMoa050516 (Pubitemid 41770166)
57. Sandborn W. J., Rutgeerts P., Feagan B. G., Reinisch W., Olson A., Johanns J., Lu J., Horgan K., Rachmilewitz D., Hanauer S. B., Lichtenstein G. R., de Villiers W. J. S., Present D., Sands B. E., Colombel J. F., Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009 137 4 1250 1260 2-s2.0-70349418632 10.1053/j.gastro.2009.06.061
58. Bamias G., Marini M., Moskaluk C. A., Odashima M., Ross W. G., Rivera-Nieves J., Cominelli F., Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. Journal of Immunology 2002 169 9 5308 5314 2-s2.0-0036841277 (Pubitemid 35217204)
59. Hollander D., Crohn's disease, TNF- α and the leaky gut. The chicken or the egg? American Journal of Gastroenterology 2002 97 8 1867 1868 2-s2.0-0036677473 10.1016/S0002-9270(02)04252-1
60. Olsen T., Cui G., Goll R., Husebekk A., Florholmen J., Infliximab therapy decreases the levels of TNF- α and IFN- γ mRNA in colonic mucosa of ulcerative colitis. Scandinavian Journal of Gastroenterology 2009 44 6 727 735 2-s2.0-67651146891 10.1080/00365520902803507
61. Xu Y., Hunt N. H., Bao S., The role of granulocyte macrophage-colony- stimulating factor in acute intestinal inflammation. Cell Research 2008 18 12 1220 1229 2-s2.0-57049185731 10.1038/cr.2008.310
62. Mahida Y. R., The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflammatory Bowel Diseases 2000 6 1 21 33 2-s2.0-0034133163
63. Ogata H., Hibi T., Cytokine and anti-cytokine therapies for inflammatory bowel disease. Current Pharmaceutical Design 2003 9 14 1107 1113 2-s2.0-0037268936 10.2174/1381612033455035 (Pubitemid 36443211)
64. Itoh J., de la Motte C., Strong S. A., Levine A. D., Fiocchi C., Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001 49 1 35 41 2-s2.0-0034957289 10.1136/gut.49.1.35 (Pubitemid 32601877)
65. Fuss I. J., Becker C., Yang Z., Groden C., Hornung R. L., Heller F., Neurath M. F., Strober W., Mannon P. J., Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflammatory Bowel Diseases 2006 12 1 9 15 2-s2.0-29744450121 10.1097/01.MIB.0000194183.92671.b6 (Pubitemid 43032445)
66. Bai A., Lu N., Guo Y., Chen J., Liu Z., Modulation of inflammatory response via α 2-adrenoceptor blockade in acute murine colitis. Clinical and Experimental Immunology 2009 156 2 353 362 2-s2.0-64649084323 10.1111/j.1365-2249.2009.03894.x
67. Kobayashi T., Okamoto S., Hisamatsu T., Kamada N., Chinen H., Saito R., Kitazume M. T., Nakazawa A., Sugita A., Koganei K., Isobe K., Hibi T., IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008 57 12 1682 1689 2-s2.0-56549104968 10.1136/gut.2007.135053
68. Matsumura K., Nakase H., Yamamoto S., Yoshino T., Takeda Y., Kasahara K., Ueno S., Uza N., Chiba T., Modulation of the Th1/Th2 balance by infliximab improves hyperthyroidism associated with a flareup of ulcerative colitis. Inflammatory Bowel Diseases 2009 15 7 967 968 2-s2.0-69449091637 10.1002/ibd.20760
69. Hering N. A., Schulzke J. D., Therapeutic options to modulate barrier defects in inflammatory bowel disease. Digestive Diseases 2009 27 4 450 454 2-s2.0-70449505391 10.1159/000233283
70. Schulzke J. D., Bojarski C., Zeissig S., Heller F., Gitter A. H., Fromm M., Disrupted barrier function through epithelial cell apoptosis. Annals of the New York Academy of Sciences 2006 1072 288 299 2-s2.0-33749026654 10.1196/annals.1326.027 (Pubitemid 44448461)
71. Danese S., Sans M., de la Motte C., Graziani C., West G., Phillips M. H., Pola R., Rutella S., Willis J., Gasbarrini A., Fiocchi C., Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006 130 7 2060 2073 2-s2.0-33744510694 10.1053/j.gastro.2006.03.054 (Pubitemid 43816964)
72. Medina C., Radomski M. W., Role of matrix metalloproteinases in intestinal inflammation. Journal of Pharmacology and Experimental Therapeutics 2006 318 3 933 938 2-s2.0-33747626518 10.1124/jpet.106.103465 (Pubitemid 44268297)
73. Brew K., Nagase H., The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochimica et Biophysica Acta 2010 1803 1 55 71 2-s2.0-77049113770 10.1016/j.bbamcr.2010.01. 003
74. Pineton De Chambrun G., Peyrin-Biroulet L., Lémann M., Colombel J. F., Clinical implications of mucosal healing for the management of IBD. Nature Reviews Gastroenterology and Hepatology 2010 7 1 15 29 2-s2.0-75049086190 10.1038/nrgastro.2009.203
75. Atreya I., Atreya R., Neurath M. F., NF- B in inflammatory bowel disease. Journal of Internal Medicine 2008 263 6 591 596 2-s2.0-43549085501 10.1111/j.1365-2796.2008.01953.x (Pubitemid 351678589)
76. Hollenbach E., Neumann M., Vieth M., Roessner A., Malfertheiner P., Naumann M., Inhibition of p38 MAP kinase- and RICK/NF- B-signaling suppresses inflammatory bowel disease. The FASEB Journal 2004 18 13 1550 1552 2-s2.0-9444228220 10.1096/fj.04-1642fje (Pubitemid 39561629)
77. Bantel H., Domschke W., Schulze-Osthoff K., Kaskas B., Gregor M., Abnormal activation of transcription factor NF- B involved in steroid resistance in chronic inflammatory bowel disease. American Journal of Gastroenterology 2000 95 7 1845 1846 2-s2.0-0033930261 10.1016/S0002-9270(00)00935-7 (Pubitemid 30485038)
78. Broom O. J., Widjaya B., Troelsen J., Olsen J., Nielsen O. H., Mitogen activated protein kinases: a role in inflammatory bowel disease? Clinical and Experimental Immunology 2009 158 3 272 280 2-s2.0-70350586944 10.1111/j.1365-2249.2009.04033.x
79. Wilmanski J. M., Petnicki-Ocwieja T., Kobayashi K. S., NLR proteins: integral members of innate immunity and mediators of inflammatory diseases. Journal of Leukocyte Biology 2008 83 1 13 30 2-s2.0-38149113537 10.1189/jlb.0607402
80. Hoffmeyer A., Grosse-Wilde A., Flory E., Neufeld B., Kunz M., Rapp U. R., Ludwig S., Different mitogen-activated protein kinase signaling pathways cooperate to regulate tumor necrosis factor α gene expression in T lymphocytes. Journal of Biological Chemistry 1999 274 7 4319 4327 2-s2.0-0033548249 10.1074/jbc.274.7.4319 (Pubitemid 29090967)
81. Siegel C. A., Melmed G. Y., Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therapeutic Advances in Gastroenterology 2009 2 4 245 251 2-s2.0-77953440013 10.1177/1756283X09336364
82. Vermeire S., Louis E., Carbonez A., Van Assche G., Noman M., Belaiche J., De Vos M., Van Gossum A., Pescatore P., Fiasse R., Pelckmans P., Reynaert H., D'Haens G., Rutgeerts P., Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. American Journal of Gastroenterology 2002 97 9 2357 2363 2-s2.0-0036732707 10.1016/S0002-9270(02)04348-4
83. Parsi M. A., Achkar J., Richardson S., Katz J., Hammel J. P., Lashner B. A., Brzezinski A., Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002 123 3 707 713 2-s2.0-0036726041 10.1053/gast.2002.35390 (Pubitemid 34977076)
84. Arnott I. D. R., McNeill G., Satsangi J., An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Alimentary Pharmacology and Therapeutics 2003 17 12 1451 1457 2-s2.0-0037560163 10.1046/j.1365-2036.2003.01574.x (Pubitemid 36831435)
85. Fefferman D. S., Lodhavia P. J., Alsahli M., Falchuk K. R., Peppercorn M. A., Shah S. A., Farrel R. J., Smoking and immunomodulators do not influence the response or duration of response to infliximab in Chrohn's disease. Inflammatory Bowel Diseases 2004 10 4 346 351 2-s2.0-3543074116 10.1097/00054725-200407000-00004 (Pubitemid 39029176)
86. Hlavaty T., Pierik M., Henckaerts L., Ferrante M., Joossens S., Van Schuerbeek N., Noman M., Rutgeerts P., Vermeire S., Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Alimentary Pharmacology and Therapeutics 2005 22 7 613 626 2-s2.0-26244456815 10.1111/j.1365-2036.2005.02635.x (Pubitemid 41415989)
87. Franke A., McGovern D. P. B., Barrett J. C., Wang K., Radford-Smith G. L., Ahmad T., Lees C. W., Balschun T., Lee J., Roberts R., Anderson C. A., Bis J. C., Bumpstead S., Ellinghaus D., Festen E. M., Georges M., Green T., Haritunians T., Jostins L., Latiano A., Mathew C. G., Montgomery G. W., Prescott N. J., Raychaudhuri S., Rotter J. I., Schumm P., Sharma Y., Simms L. A., Taylor K. D., Whiteman D., Wijmenga C., Baldassano R. N., Barclay M., Bayless T. M., Brand S., Büning C., Cohen A., Colombel J. F., Cottone M., Stronati L., Denson T., De Vos M., D'Inca R., Dubinsky M., Edwards C., Florin T., Franchimont D., Gearry R., Glas J., Van Gossum A., Guthery S. L., Halfvarson J., Verspaget H. W., Hugot J. P., Karban A., Laukens D., Lawrance I., Lemann M., Levine A., Libioulle C., Louis E., Mowat C., Newman W., Panés J., Phillips A., Proctor D. D., Regueiro M., Russell R., Rutgeerts P., Sanderson J., Sans M., Seibold F., Steinhart A. H., Stokkers P. C. F., Torkvist L., Kullak-Ublick G., Wilson D., Walters T., Targan S. R., Brant S. R., Rioux J. D., D'Amato M., Weersma R. K., Kugathasan S., Griffiths A. M., Mansfield J. C., Vermeire S., Duerr R. H., Silverberg M. S., Satsangi J., Schreiber S., Cho J. H., Annese V., Hakonarson H., Daly M. J., Parkes M., Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics 2010 42 12 1118 1125 2-s2.0-78649489009 10.1038/ng.717
88. Dubinsky M. C., Mei L., Friedman M., Dhere T., Haritunians T., Hakonarson H., Kim C., Glessner J., Targan S. R., McGovern D. P., Taylor K. D., Rotter J. I., Genome Wide Association (GWA) predictors of anti-TNF α therapeutic responsiveness in pediatric inflammatory bowel desease. Inflammatory Bowel Diseases 2010 16 8 1357 1366 2-s2.0-77953787089 10.1002/ibd.21174
89. Parashette K. R., Makam R. C., Cuffari C., Infliximab therapy in pediatric Crohn's disease: a review. Clinical and Experimental Gastroenterology 2010 3 1 57 63 2-s2.0-77955464751
90. Bouchaud G., Mortier E., Flamant M., Barbieux I., Plet A., Galmiche J. P., Jacques Y., Bourreille A., Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease. Gastroenterology 2010 138 7 2378 2387 2-s2.0-77952832453 10.1053/j.gastro.2010.02.044
91. Siddiqui M. A. A., The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Current Opinion in Rheumatology 2007 19 3 308 313 2-s2.0-34247165137 10.1097/01.bor.0000265447.48722.04 (Pubitemid 46597472)
92. Gartlehner G., Hansen R. A., Jonas B. L., Thieda P., Lohr K. N., Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clinical Rheumatology 2008 27 1 67 76 2-s2.0-36549065772 10.1007/s10067-007-0654-6 (Pubitemid 350182680)